Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 9/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.47 |
| ▸ | RAB9A | P51151 | 7/20 | 0.47 |
| ▸ | NPC1 | O15118 | 7/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | PKM | P14618 | 2/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1298605 | 0.85 | MAPT (0.66) | MAPTTP53MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1298603 | 0.85 | MAPT (0.66) | MAPTTP53MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31252955 | 0.85 | MAPT (0.66) | MAPTTP53MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL15624226 | 0.74 | NPC1 (0.73) | MAPTTP53MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13994724 | 0.72 | HDAC6 (0.59) | MAPTTP53MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31252953 | 0.72 | MAPT (0.71) | MAPTTP53MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2497906 | 0.72 | MAPT (0.71) | MAPTTP53MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2497904 | 0.72 | MAPT (0.71) | MAPTTP53MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31305038 | 0.71 | NPC1 (0.89) | MAPTTP53MEN1KMT2ASMN1; SMN2 | |
| Sulfuric Acid SCHEMBL6482500 | 0.71 | NPC1 (0.64) | MAPTTP53MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12624089-B2 | Antigen-binding molecule for promoting disappearance of antigen via FcγRIIB | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2026-05-12 | — | — | US | disclosed |
| US-20250387530-A1 | RADIOPAQUE MONOMER AND EMBOLISATION MICROSPHERES COMPRISING SAME | GUERBET (FR) | 2025-12-25 | — | — | US | disclosed |
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | DRAUPNIR BIO APS (DK) | 2025-11-13 | — | — | US | disclosed |
| EP-4543858-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | Draupnir Bio ApS (DK) | 2025-04-30 | — | — | EP | disclosed |
| EP-4299080-A1 | RADIO-OPAQUE MONOMER AND EMBOLISATION MICROSPHERES COMPRISING SAME | Guerbet (FR) | 2024-01-03 | — | — | EP | disclosed |
| WO-2023247754-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | DRAUPNIR BIO APS (DK) | 2023-12-28 | — | — | WO | disclosed |
| US-20230140797-A1 | ANTIGEN-BINDING MOLECULE FOR PROMOTING DISAPPEARANCE OF ANTIGEN VIA Fc GAMMA RIIB | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250387530-A1 | RADIOPAQUE MONOMER AND EMBOLISATION MICROSPHERES COMPRISING SAME | MSR1, FGB, FLT1 | MAPT 4396/4885TP53 4356/4885MEN1 506/4885 |
| US-20250345446-A1 | BIFUNCTIONAL MOLECULES THAT SELECTIVELY INDUCE DEGRADATION OF EXTRACELLULAR TARGETS IN LYSOSOMES | SORT1, SCARB1, LAMP1 | MAPT 3361/4885TP53 733/4885MEN1 2813/4885 |
| US-12624089-B2 | Antigen-binding molecule for promoting disappearance of antigen via FcγRIIB | FCGR3B, FCGR2A, FCER2 | MAPT 1734/4885TP53 947/4885MEN1 3204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.